Psilocybin in Healthy Older Adults

The Psilocybin Healthy Older Adults Study is a Phase 1 trial examining the safety and pharmacokinetic characteristics of psilocybin in healthy older adults, with results informing selection of drug(s) and doses for later efficacy trials aimed at treating chronic back pain and cancer-related bone pain. Participants in this study will receive two doses of oral psilocybin (Cohort 1a: 10mg then 25mg; Cohort 1b: 15mg then 30mg). Total study duration, including screening and follow-up data collection, will span up to 20 weeks. Along with two dosing sessions, participants will attend two preparatory sessions (1.5-2 hours each) and four integration sessions (two after each dosing; 1-1.5 hours each). 

• Symptoms/Population: Healthy older adults (aged 65-85 years old)
• Eligibility requirements:
  • Inclusion criteria: 65-85 years old; generally healthy; have an identified support person; capacity to consent
  • Exclusion criteria: unstable medical conditions or serious lab abnormalities; risk for hypertensive crisis; CNS pathology; primary psychotic or affective psychotic disorders; family history of psychotic or bipolar spectrum illnesses; substance use disorder; extensive psychedelic use; significant risk of suicide; concomitant medications.